摘要:
A pharmaceutical formulation, comprising agomelatine in the form of agamelatine co-crystal with a co-crystal former selected from the group of organic acids in an amount corresponding to 15 - 22 mg agomelatitte dose per one dosage unit and at least one pharmaceutically acceptable excipient for effective treatment of diseases responsive to therapy by agomelatine.